N/A
Manufactured by Neurocrine Biosciences, Inc.
34,810 FDA adverse event reports analyzed
Last updated: 2026-04-14
VALBENAZINE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Neurocrine Biosciences, Inc.. The most commonly reported adverse reactions for VALBENAZINE include DRUG INEFFECTIVE, SOMNOLENCE, FATIGUE, TREMOR, TARDIVE DYSKINESIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for VALBENAZINE.
Out of 24,300 classified reports for VALBENAZINE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 34,810 FDA FAERS reports that mention VALBENAZINE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, SOMNOLENCE, FATIGUE, TREMOR, TARDIVE DYSKINESIA, FALL. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Neurocrine Biosciences, Inc. in connection with VALBENAZINE. Always verify the specific product and NDC with your pharmacist.